Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children`s Oncology Group
Abstract PURPOSESurgery is curative therapy for pediatric low-grade gliomas (LGGs) in areas of the brain amenable to complete resection.
However, LGGs located in areas where complete resection is not possible can threaten both function and life.
The purpose of this study was to compare two chemotherapy regimens for LGGs in children younger than age 10 years for whom radiotherapy was felt by the practitioner to pose a high risk of neurodevelopmental injury.
PATIENTS AND METHODSPreviously untreated children younger than age 10 years with progressive or residual LGGs were eligible.
Children were randomly assigned to receive carboplatin and vincristine (CV) or thioguanine, procarbazine, lomustine, and vincristine (TPCV).
Children with neurofibromatosis are reported separately.ResultsOf 274 randomly assigned patients who met eligibility requirements, 137 received CV and 137 received TPCV.
The 5-year event-free survival (EFS) and overall survival (OS) rates for all eligible patients were 45% Â± 3.2% and 86% Â± 2.2%, respectively.
The 5-year EFS rates were 39% Â± 4% for CV and 52% Â± 5% for TPCV (stratified log-rank test P = .10; cure model analysis P = .007).
On multivariate analysis, factors independently predictive of worse EFS and OS were younger age and tumor size greater than 3 cm(2).
CONCLUSIONThe difference in EFS between the regimens did not reach significance on the basis of the stratified log-rank test.